What's Happening?
Karyopharm Therapeutics is pursuing an expansion of its blood cancer drug, Xpovio, to treat myelofibrosis, following mixed results from the SENTRY trial. The trial showed that Xpovio, when combined with Incyte's Jakafi, significantly reduced spleen volume
in patients but did not improve the absolute total symptom score compared to Jakafi plus placebo. Despite this, Karyopharm plans to meet with the FDA to discuss filing for approval based on overall survival trends, which indicated a more than 50% reduction in the risk of death at week 24. Xpovio is already approved for multiple myeloma and diffuse large B-cell lymphoma, contributing significantly to Karyopharm's revenue.
Why It's Important?
The potential approval of Xpovio for myelofibrosis could provide a new treatment option for patients, as current therapies, primarily JAK inhibitors, have limited efficacy and can cause serious side effects like anemia. Karyopharm's strategy to expand Xpovio's indications is crucial for its growth, especially as the company faces financial constraints. The mixed trial results have affected investor confidence, leading to a decline in Karyopharm's share price. However, the drug's ability to reduce spleen volume, a key treatment goal, could improve patient outcomes and overall survival, offering hope to those affected by myelofibrosis.
What's Next?
Karyopharm plans to engage with the FDA to discuss the possibility of filing for Xpovio's approval for myelofibrosis. The company is also conducting a phase 3 trial to evaluate Xpovio's efficacy in treating endometrial cancer, with results expected later this year. Financially, Karyopharm has secured a $30 million private placement to extend its operational funding into late Q3, providing some relief as it navigates these developments. The outcome of the FDA discussions and the endometrial cancer trial will be critical in determining Karyopharm's future trajectory.
